Le Foll Bernard, Justinova Zuzana, Wertheim Carrie E, Barnes Chanel, Goldberg Steven R
Preclinical Pharmacology Section, Intramural Research Program, National Institute on Drug Abuse, Baltimore, Maryland, USA.
Behav Pharmacol. 2008 Feb;19(1):13-20. doi: 10.1097/FBP.0b013e3282f3cf84.
The effects of topiramate, a potential treatment for drug dependence, were evaluated in two groups of rats trained to discriminate the administration of either 0.4 mg/kg nicotine or 10 mg/kg cocaine from that of saline, under a fixed-ratio 10 schedule of food delivery. Topiramate (1-60 mg/kg, intraperitoneal) did not produce any nicotine-like or cocaine-like discriminative effects by itself and did not produce any shift in the dose-response curves for nicotine or cocaine discrimination. Thus, the ability to discriminate the effects of nicotine or cocaine does not appear to be altered by topiramate administration. Furthermore, topiramate, given either alone or in combination with nicotine or cocaine, did not depress rates of responding. These experiments indicate that topiramate does not enhance or reduce the ability of rats to discriminate the effects of nicotine or cocaine.
在两组大鼠中评估了托吡酯(一种潜在的药物依赖治疗药物)的效果。这两组大鼠在固定比例为10的食物投递计划下,经过训练能够区分0.4毫克/千克尼古丁或10毫克/千克可卡因与生理盐水的给药情况。托吡酯(1 - 60毫克/千克,腹腔注射)本身未产生任何类似尼古丁或可卡因的辨别效应,也未使尼古丁或可卡因辨别剂量 - 反应曲线发生任何偏移。因此,给予托吡酯似乎不会改变辨别尼古丁或可卡因效应的能力。此外,单独给予托吡酯或与尼古丁或可卡因联合给予时,均未降低反应率。这些实验表明,托吡酯不会增强或降低大鼠辨别尼古丁或可卡因效应的能力。